We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where Elevance Health, Inc. (NYSE:ELV) stands against other best stocks that will always grow.

The Looming Risk of a Recession in the US

Threats of an impending recession are looming over the stock market due to Trump’s tariffs and macroeconomic uncertainty. According to CNBC’s quarterly CFO Council Survey for Q1 2025, a majority of chief financial officers are of the opinion that the economy is likely to fall into a recession in H2 2025. The CFOs said that they were generally “pessimistic” about the overall state of the American economy, and expressed uncertainty about the stock market.

The survey also showed that 95% of the CFOs claimed that their ability to make business decisions is being affected by policy, and a significant number said that although the Trump administration is “delivering on promises,” the government’s dealing with such matters is proving disruptive, extreme, and too chaotic. This is causing considerable difficulty to businesses looking to effectively navigate the present challenges. Therefore, around 60% of the CFOs opined that they expect a recession to materialize in H2 2025; another 15% said that it may appear in 2026.

CNBC reported on April 16 that Fed Chair Jerome Powell announced the day before that the central bank may be caught at the crossroads of supporting economic growth and controlling inflation. He said that although he anticipates lower growth and increased inflation, it is uncertain where the Fed will need to focus its attention. In prepared remarks before the Economic Club of Chicago, he said:

“We may find ourselves in the challenging scenario in which our dual-mandate goals are in tension. If that were to occur, we would consider how far the economy is from each goal, and the potentially different time horizons over which those respective gaps would be anticipated to close.”

Powell also did not give any indication of where interest rates could be headed, but remarked that:

“For the time being, we are well positioned to wait for greater clarity before considering any adjustments to our policy stance.”

READ ALSO: 15 Best Blue Chip Stocks to Buy According to Billionaires and 11 Best Retail Stocks to Buy Right Now.

Are the Stagflation Risks Real?

On April 17, Joyce Chang, JPMorgan chair of global research, appeared on CNBC’s ‘Closing Bell Overtime’ to talk about Powell’s latest comments and the looming risk of recession. She was of the opinion that the risk of the recession is hovering over the stock market even with Trump’s 90-day tariff delays at around 60%.

Chang said that PCE inflation is coming towards 4% over the next year, with growth flat at the end of the year. While a recession is not imminent, as some of the hard data is still looking relatively healthy, with higher inflation, flat growth, and still very high fiscal deficits, one has to highlight that the stagflation risks are very real. The uncertainty would continue and is highly unlikely to be over after 90 days.

Since current and future market conditions reflect volatility and uncertainty, let’s examine the 10 best stocks that might always grow, even in an economic downturn.

Our Methodology

We sifted through stock screeners, financial media reports, and ETFs to compile a list of 20 recession-proof stocks with a 10-year revenue growth rate of 8%-15% and chose the top 10 most popular among hedge funds as of Q4 2024. The list is ordered in ascending order of hedge fund sentiment. We sourced the hedge fund sentiment data from Insider Monkey’s database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Elevance Health, Inc. (NYSE:ELV)

Number of Hedge Fund Holders: 73

Elevance Health, Inc. (NYSE:ELV) is a health company that operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a range of health plans and services, while the CarelonRx segment manages pharmacy services. The Carelon Services segment offers various healthcare-related services by integrating behavioral, physical, pharmacy, and social services.

On April 21, Truist Financial analyst Jailendra Singh reiterated a Buy rating on Elevance Health, Inc. (NYSE:ELV). Leerink Partners analyst Whit Mayo also reiterated a Buy rating on the company on April 18, setting a price target of $463.00. The analyst expressed confidence in the company’s full-year estimates, which remain unaffected despite the ongoing investor concerns regarding Medicaid margin recovery and cost trends.

The company also has solid operations. Its operating revenue rose $2.5 billion, or 6%, to $45.0 billion compared to the prior-year quarter while operating income for the year reached $175.2 billion, up $5.0 billion, or 3%. This growth was attributed to higher premium yields in Elevance Health, Inc.’s (NYSE:ELV) Health Benefits segment, growth in CarelonRx product revenue, and acquisitions undertaken in 2024.

Artisan Select Equity Fund also expressed bullish sentiments for the stock, stating that its challenges are expected to be temporary. Rates of Medicaid services are anticipated to move up over the coming 12 to 18 months, supporting the recovery of the company’s margins. It stated the following regarding Elevance Health, Inc. (NYSE:ELV) in its Q4 2024 investor letter:

“Elevance Health, Inc. (NYSE:ELV) took a couple of blows this quarter. First, it warned that its Medicaid earnings would come in below expectations this year. The Medicaid business has been in the spotlight as a result of COVID-19. Medicaid rolls filled up during the pandemic, but then rolls started to come down as enrollees lost eligibility when the economy began normalizing. This has made estimating the severity and health trends of the remaining population difficult. So far this year, cost trends have been much worse than expected and are out of line with Elevance’s approved rate structure. Margins in the Medicaid business, therefore, will be down this year, and overall profits are likely to be flat. We believe this is a temporary situation. State Medicaid programs are legally required to pay actuarially sound rates to the providers of Medicaid services, such as Elevance. Rates are expected, therefore, to move upward over the next 12 to 18 months, restoring Elevance’s margins to a more normal level.

The second issue for Elevance is investor sentiment. A mentally deranged young man murdered top executive of United Healthcare, the largest health insurer in the country. This led to an Internet frenzy of vicious, inaccurate and, frankly, deplorable criticisms of health insurance companies and their executives. Negative and controversial headlines tend to hurt share prices. This was true of Elevance’s stock in the aftermath of this heinous crime. The share price has fallen to extremely attractive levels, trading currently at about 11X earnings. We added to our position during this weakness.”

Overall, ELV ranks 9th on our list of the best stocks that will always grow. While we acknowledge the potential for ELV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ELV but trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.